Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

  1. Aroda, V.R.
  2. Ahmann, A.
  3. Cariou, B.
  4. Chow, F.
  5. Davies, M.J.
  6. Jódar, E.
  7. Mehta, R.
  8. Woo, V.
  9. Lingvay, I.
Aldizkaria:
Diabetes and Metabolism

ISSN: 1878-1780,  1262-3636

Argitalpen urtea: 2019

Alea: 45

Zenbakia: 5

Orrialdeak: 409-418

Mota: Berrikuspena

DOI: 10.1016/J.DIABET.2018.12.001 GOOGLE SCHOLAR
Datuen iturria: Scopus